-
1
-
-
65349195631
-
The obesity, metabolic syndrome, and type 2 diabetes mellitus pandemic: Part I. Increased cardiovascular disease risk and the importance of atherogenic dyslipidemia in persons with the metabolic syndrome and type 2 diabetes mellitus
-
Ginsberg HN, MacCallum PR, Henry N. The obesity, metabolic syndrome, and type 2 diabetes mellitus pandemic: Part I. Increased cardiovascular disease risk and the importance of atherogenic dyslipidemia in persons with the metabolic syndrome and type 2 diabetes mellitus. J Cardiometab Syndr 2009;4:113-119.
-
(2009)
J Cardiometab Syndr
, vol.4
, pp. 113-119
-
-
Ginsberg, H.N.1
MacCallum, P.R.2
Henry, N.3
-
2
-
-
74049143053
-
Glucose, obesity, metabolic syndrome, and diabetes relevance to incidence of heart failure
-
Horwich TB, Fonarow GC. Glucose, obesity, metabolic syndrome, and diabetes relevance to incidence of heart failure. J Am Coll Cardiol 2010;55:283-293.
-
(2010)
J Am Coll Cardiol
, vol.55
, pp. 283-293
-
-
Horwich, T.B.1
Fonarow, G.C.2
-
3
-
-
44649098307
-
Lipoprotein management in patients with cardiometabolic risk: Consensus statement from the American Diabetes Association and the American College of Cardiology Foundation
-
Brunzell JD, Davidson M, Furberg CD, et al. Lipoprotein management in patients with cardiometabolic risk: Consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care 2008;31:811-822.
-
(2008)
Diabetes Care
, vol.31
, pp. 811-822
-
-
Brunzell, J.D.1
Davidson, M.2
Furberg, C.D.3
-
4
-
-
79960539641
-
ESC/EAS guidelines for the management of dyslipidaemias: The task force for the management of dyslipidaemias of the European society of cardiology (ESC) and the European atherosclerosis society (EAS)
-
Reiner Ž, Catapano AL, De Backer G, et al. ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011;32: 1769-1818.
-
(2011)
Eur Heart J
, vol.32
, pp. 1769-1818
-
-
Reiner, Z.1
Catapano, A.L.2
De Backer, G.3
-
5
-
-
78650223573
-
Atherogenic dyslipidemia: Cardiovascular risk and dietary intervention
-
Musunuru K. Atherogenic dyslipidemia: Cardiovascular risk and dietary intervention. Lipids 2010;45:907-914.
-
(2010)
Lipids
, vol.45
, pp. 907-914
-
-
Musunuru, K.1
-
8
-
-
79955562491
-
Metabolic syndrome: Definitions and controversies
-
Kassi E, Pervanidou P, Kaltsas G, et al. Metabolic syndrome: Definitions and controversies. BMC Med 2011;9:48.
-
(2011)
BMC Med
, vol.9
, pp. 48
-
-
Kassi, E.1
Pervanidou, P.2
Kaltsas, G.3
-
9
-
-
33846422032
-
Obesity and diabetes in the developing world-A growing challenge
-
Hossain P, Kawar B, El NM. Obesity and diabetes in the developing world-a growing challenge. N Engl J Med 2007;356:213-215.
-
(2007)
N Engl J Med
, vol.356
, pp. 213-215
-
-
Hossain, P.1
Kawar, B.2
El, N.M.3
-
10
-
-
55849137212
-
Obesity and the metabolic syndrome in developing countries
-
Misra A, Khurana L. Obesity and the metabolic syndrome in developing countries. J Clin Endocrinol Metab 2008;93(Suppl 1):S9-S30.
-
(2008)
J Clin Endocrinol Metab
, vol.93
, pp. S9-S30
-
-
Misra, A.1
Khurana, L.2
-
11
-
-
84880375219
-
Obesity and dyslipidemia in South Asians
-
Misra A, Shrivastava U. Obesity and dyslipidemia in South Asians. Nutrients 2013;5:2708-2733.
-
(2013)
Nutrients
, vol.5
, pp. 2708-2733
-
-
Misra, A.1
Shrivastava, U.2
-
12
-
-
79960202841
-
Type 2 diabetes across generations: From pathophysiology to prevention and management
-
Nolan CJ, Damm P, Prentki M. Type 2 diabetes across generations: From pathophysiology to prevention and management. Lancet 2011;378:169-181.
-
(2011)
Lancet
, vol.378
, pp. 169-181
-
-
Nolan, C.J.1
Damm, P.2
Prentki, M.3
-
13
-
-
75149180515
-
Standards of medical care in diabetes-2010
-
American Diabetes Association. Standards of medical care in diabetes-2010. Diabetes Care 2010;33(Suppl 1): S11-S61.
-
(2010)
Diabetes Care
, vol.33
, pp. S11-S61
-
-
-
14
-
-
79955634896
-
-
Abbreviated report of a World Health Organization (WHO) consultation
-
World Health Organization. Use of glycated haemoglobin (HbA1c) in the diagnosis of diabetes mellitus. Abbreviated report of a World Health Organization (WHO) consultation. 2013. Available at http://whoint/diabetes/publications/report-hba1c-2011pdf
-
(2013)
Use of Glycated Haemoglobin (HbA1c) in the Diagnosis of Diabetes Mellitus
-
-
-
16
-
-
84862302432
-
Prediabetes: A high-risk state for diabetes development
-
Tabak AG, Herder C, Rathmann W, et al. Prediabetes: A high-risk state for diabetes development. Lancet 2012;379: 2279-2290.
-
(2012)
Lancet
, vol.379
, pp. 2279-2290
-
-
Tabak, A.G.1
Herder, C.2
Rathmann, W.3
-
17
-
-
0024160877
-
Banting lecture 1988. Role of insulin resistance in human disease
-
Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988;37:1595-1607.
-
(1988)
Diabetes
, vol.37
, pp. 1595-1607
-
-
Reaven, G.M.1
-
18
-
-
24144484876
-
The metabolic syndrome: Time for a critical appraisal: Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes
-
Kahn R, Buse J, Ferrannini E, et al. The metabolic syndrome: Time for a critical appraisal: Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2005;28:2289-2304.
-
(2005)
Diabetes Care
, vol.28
, pp. 2289-2304
-
-
Kahn, R.1
Buse, J.2
Ferrannini, E.3
-
19
-
-
34247193564
-
Metabolic syndrome: Is it a syndrome? Does it matter?
-
Kahn R. Metabolic syndrome: Is it a syndrome? Does it matter? Circulation 2007;115:1806-1810.
-
(2007)
Circulation
, vol.115
, pp. 1806-1810
-
-
Kahn, R.1
-
20
-
-
0032510639
-
Prediction of coronary heart disease using risk factor categories
-
Wilson PW, D'Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998;97:1837-1847.
-
(1998)
Circulation
, vol.97
, pp. 1837-1847
-
-
Wilson, P.W.1
D'Agostino, R.B.2
Levy, D.3
-
21
-
-
70350245011
-
Harmonizing the metabolic syndrome: A joint interim statement of the international diabetes federation task force on epidemiology and prevention; National heart, lung, and blood institute; American heart association; World heart federation; International atherosclerosis society; And international association for the study of obesity
-
Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009;120:1640-1645.
-
(2009)
Circulation
, vol.120
, pp. 1640-1645
-
-
Alberti, K.G.1
Eckel, R.H.2
Grundy, S.M.3
-
22
-
-
33644872972
-
Familial hypercholesterolemia: A challenge of diagnosis and therapy
-
Sibley C, Stone NJ. Familial hypercholesterolemia: A challenge of diagnosis and therapy. Cleve Clin J Med 2006; 73:57-64.
-
(2006)
Cleve Clin J Med
, vol.73
, pp. 57-64
-
-
Sibley, C.1
Stone, N.J.2
-
23
-
-
79957977001
-
Array-based resequencing for mutations causing familial hypercholesterolemia
-
Chiou KR, Charng MJ, Chang HM. Array-based resequencing for mutations causing familial hypercholesterolemia. Atherosclerosis 2011;216:383-389.
-
(2011)
Atherosclerosis
, vol.216
, pp. 383-389
-
-
Chiou, K.R.1
Charng, M.J.2
Chang, H.M.3
-
24
-
-
26244432388
-
Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins
-
Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-1278.
-
(2005)
Lancet
, vol.366
, pp. 1267-1278
-
-
Baigent, C.1
Keech, A.2
Kearney, P.M.3
-
25
-
-
43249113169
-
Familial combined hyperlipidaemia: Under-defined and underdiagnosed?
-
Wierzbicki AS, Graham CA, Young IS, et al. Familial combined hyperlipidaemia: Under-defined and underdiagnosed? Curr Vasc Pharmacol 2008;6:13-22.
-
(2008)
Curr Vasc Pharmacol
, vol.6
, pp. 13-22
-
-
Wierzbicki, A.S.1
Graham, C.A.2
Young, I.S.3
-
27
-
-
84860235809
-
Association of alcohol consumption with lipid profile in hypertensive men
-
Park H, Kim K. Association of alcohol consumption with lipid profile in hypertensive men. Alcohol Alcohol 2012;47:282-287.
-
(2012)
Alcohol Alcohol
, vol.47
, pp. 282-287
-
-
Park, H.1
Kim, K.2
-
28
-
-
79955430659
-
Comparison of the relationships of alcohol intake with atherosclerotic risk factors in men with and without diabetes mellitus
-
Wakabayashi I. Comparison of the relationships of alcohol intake with atherosclerotic risk factors in men with and without diabetes mellitus. Alcohol Alcohol 2011;46: 301-307.
-
(2011)
Alcohol Alcohol
, vol.46
, pp. 301-307
-
-
Wakabayashi, I.1
-
29
-
-
0036070865
-
Hyperlipidaemic state and cardiovascular risk in primary biliary cirrhosis
-
Longo M, Crosignani A, Battezzati PM, et al. Hyperlipidaemic state and cardiovascular risk in primary biliary cirrhosis. Gut 2002;51:265-269.
-
(2002)
Gut
, vol.51
, pp. 265-269
-
-
Longo, M.1
Crosignani, A.2
Battezzati, P.M.3
-
30
-
-
0026031716
-
Lipid abnormalities in renal disease
-
Appel G. Lipid abnormalities in renal disease. Kidney Int 1991;39:169-183.
-
(1991)
Kidney Int
, vol.39
, pp. 169-183
-
-
Appel, G.1
-
31
-
-
0027319164
-
The nephrotic syndrome, lipids, and risk factors for cardiovascular disease
-
Radhakrishnan J, Appel AS, Valeri A, et al. The nephrotic syndrome, lipids, and risk factors for cardiovascular disease. Am J Kidney Dis 1993;22:135-142.
-
(1993)
Am J Kidney Dis
, vol.22
, pp. 135-142
-
-
Radhakrishnan, J.1
Appel, A.S.2
Valeri, A.3
-
32
-
-
0028288403
-
Lipid abnormalities in the nephrotic syndrome: Causes, consequences, and treatment
-
Wheeler DC, Bernard DB. Lipid abnormalities in the nephrotic syndrome: Causes, consequences, and treatment. Am J Kidney Dis 1994;23:331-346.
-
(1994)
Am J Kidney Dis
, vol.23
, pp. 331-346
-
-
Wheeler, D.C.1
Bernard, D.B.2
-
33
-
-
0027162504
-
Hyperlipidemia in patients with primary and secondary hypothyroidism
-
O'Brien T, Dinneen SF, O'Brien PC, et al. Hyperlipidemia in patients with primary and secondary hypothyroidism. Mayo Clin Proc 1993;68:860-866.
-
(1993)
Mayo Clin Proc
, vol.68
, pp. 860-866
-
-
O'Brien, T.1
Dinneen, S.F.2
O'Brien, P.C.3
-
34
-
-
0033397395
-
The effects of clozapine on levels of total cholesterol and related lipids in serum of patients with schizophrenia: A prospective study
-
Dursun SM, Szemis A, Andrews H, et al. The effects of clozapine on levels of total cholesterol and related lipids in serum of patients with schizophrenia: A prospective study. J Psychiatry Neurosci 1999;24:453-455.
-
(1999)
J Psychiatry Neurosci
, vol.24
, pp. 453-455
-
-
Dursun, S.M.1
Szemis, A.2
Andrews, H.3
-
35
-
-
0028896514
-
Effects of antihypertensive therapy on serum lipids
-
Kasiske BL, Ma JZ, Kalil RS, et al. Effects of antihypertensive therapy on serum lipids. Ann Intern Med 1995; 122:133-141.
-
(1995)
Ann Intern Med
, vol.122
, pp. 133-141
-
-
Kasiske, B.L.1
Ma, J.Z.2
Kalil, R.S.3
-
36
-
-
84864131448
-
Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel
-
Thompson MA, Aberg JA, Hoy JF, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA 2012;308:387-402.
-
(2012)
JAMA
, vol.308
, pp. 387-402
-
-
Thompson, M.A.1
Aberg, J.A.2
Hoy, J.F.3
-
38
-
-
0031014495
-
Small LDL, atherogenic dyslipidemia, and the metabolic syndrome
-
Grundy SM. Small LDL, atherogenic dyslipidemia, and the metabolic syndrome. Circulation 1997;95:1-4.
-
(1997)
Circulation
, vol.95
, pp. 1-4
-
-
Grundy, S.M.1
-
39
-
-
0031935662
-
An overview of reverse cholesterol transport
-
Tall AR. An overview of reverse cholesterol transport. Eur Heart J 1998;19(Suppl A):A31-A35.
-
(1998)
Eur Heart J
, vol.19
, pp. A31-A35
-
-
Tall, A.R.1
-
40
-
-
0024501678
-
Highdensity lipoprotein cholesterol and cardiovascular disease. Four prospective American studies
-
Gordon DJ, Probstfield JL, Garrison RJ, et al. Highdensity lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989;79: 8-15.
-
(1989)
Circulation
, vol.79
, pp. 8-15
-
-
Gordon, D.J.1
Probstfield, J.L.2
Garrison, R.J.3
-
41
-
-
34748887666
-
HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events
-
Barter P, Gotto AM, LaRosa JC, et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 2007;357:1301-1310.
-
(2007)
N Engl J Med
, vol.357
, pp. 1301-1310
-
-
Barter, P.1
Gotto, A.M.2
Larosa, J.C.3
-
42
-
-
85027956925
-
Triglycerides and cardiovascular disease: A scientific statement from the American Heart Association
-
Miller M, Stone NJ, Ballantyne C, et al. Triglycerides and cardiovascular disease: A scientific statement from the American Heart Association. Circulation 2011;123:2292-2333.
-
(2011)
Circulation
, vol.123
, pp. 2292-2333
-
-
Miller, M.1
Stone, N.J.2
Ballantyne, C.3
-
43
-
-
84893127732
-
Assessing the clinical benefits of lipid-disorder drugs
-
Hiatt WR, Smith RJ. Assessing the clinical benefits of lipid-disorder drugs. N Engl J Med 2014;370:396-399.
-
(2014)
N Engl J Med
, vol.370
, pp. 396-399
-
-
Hiatt, W.R.1
Smith, R.J.2
-
45
-
-
81255137973
-
The role of triglycerides in atherosclerosis
-
Talayero BG, Sacks FM. The role of triglycerides in atherosclerosis. Curr Cardiol Rep 2011;13:544-552.
-
(2011)
Curr Cardiol Rep
, vol.13
, pp. 544-552
-
-
Talayero, B.G.1
Sacks, F.M.2
-
46
-
-
0031032723
-
Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study
-
Lamarche B, Tchernof A, Moorjani S, et al. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study. Circulation 1997;95: 69-75.
-
(1997)
Circulation
, vol.95
, pp. 69-75
-
-
Lamarche, B.1
Tchernof, A.2
Moorjani, S.3
-
47
-
-
82955247909
-
IDF diabetes atlas: Global estimates of the prevalence of diabetes for 2011 and 2030
-
Whiting DR, Guariguata L, Weil C, et al. IDF diabetes atlas: Global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 2011;94:311-321.
-
(2011)
Diabetes Res Clin Pract
, vol.94
, pp. 311-321
-
-
Whiting, D.R.1
Guariguata, L.2
Weil, C.3
-
48
-
-
2342466734
-
Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030
-
Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27:1047-1053.
-
(2004)
Diabetes Care
, vol.27
, pp. 1047-1053
-
-
Wild, S.1
Roglic, G.2
Green, A.3
-
49
-
-
3142735789
-
The independent effect of type 2 diabetes mellitus on ischemic heart disease, stroke, and death: A population-based study of 13,000 men and women with 20 years of follow-up
-
Almdal T, Scharling H, Jensen JS, et al. The independent effect of type 2 diabetes mellitus on ischemic heart disease, stroke, and death: A population-based study of 13,000 men and women with 20 years of follow-up. Arch Intern Med 2004;164:1422-1426.
-
(2004)
Arch Intern Med
, vol.164
, pp. 1422-1426
-
-
Almdal, T.1
Scharling, H.2
Jensen, J.S.3
-
50
-
-
0042671239
-
Cardiovascular disease and diabetes
-
Bloomgarden ZT. Cardiovascular disease and diabetes. Diabetes Care 2003;26:230-237.
-
(2003)
Diabetes Care
, vol.26
, pp. 230-237
-
-
Bloomgarden, Z.T.1
-
51
-
-
0032560807
-
Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction
-
Haffner SM, Lehto S, Ronnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229-234.
-
(1998)
N Engl J Med
, vol.339
, pp. 229-234
-
-
Haffner, S.M.1
Lehto, S.2
Ronnemaa, T.3
-
52
-
-
0037407403
-
NCEPdefined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older
-
Alexander CM, Landsman PB, Teutsch SM, et al. NCEPdefined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 2003;52:1210-1214.
-
(2003)
Diabetes
, vol.52
, pp. 1210-1214
-
-
Alexander, C.M.1
Landsman, P.B.2
Teutsch, S.M.3
-
53
-
-
58849101669
-
Relationship of serum gamma-glutamyltransferase to atherogenic dyslipidemia and glycemic control in type 2 diabetes
-
Zoppini G, Targher G, Trombetta M, et al. Relationship of serum gamma-glutamyltransferase to atherogenic dyslipidemia and glycemic control in type 2 diabetes. Obesity (Silver Spring) 2009;17:370-374.
-
(2009)
Obesity (Silver Spring)
, vol.17
, pp. 370-374
-
-
Zoppini, G.1
Targher, G.2
Trombetta, M.3
-
54
-
-
84866738927
-
Hypertriglyceridemia and residual dyslipidemia in statin-treated, patients with diabetes at the highest risk for cardiovascular disease and achieving very-low low-density lipoproteincholesterol levels
-
Querton L, Buysschaert M, Hermans MP. Hypertriglyceridemia and residual dyslipidemia in statin-treated, patients with diabetes at the highest risk for cardiovascular disease and achieving very-low low-density lipoproteincholesterol levels. J Clin Lipidol 2012;6:434-442.
-
(2012)
J Clin Lipidol
, vol.6
, pp. 434-442
-
-
Querton, L.1
Buysschaert, M.2
Hermans, M.P.3
-
55
-
-
84873868818
-
Joint prevalence of diabetes, impaired glucose regulation, cardiovascular disease risk and chronic kidney disease in South Asians and White Europeans
-
Khunti K, Morris DH, Weston CL, et al. Joint prevalence of diabetes, impaired glucose regulation, cardiovascular disease risk and chronic kidney disease in South Asians and White Europeans. PLoS One 2013;8:e55580.
-
(2013)
PLoS One
, vol.8
, pp. e55580
-
-
Khunti, K.1
Morris, D.H.2
Weston, C.L.3
-
57
-
-
33845984333
-
Epidemic obesity and type 2 diabetes in Asia
-
Yoon KH, Lee JH, Kim JW, et al. Epidemic obesity and type 2 diabetes in Asia. Lancet 2006;368:1681-1688.
-
(2006)
Lancet
, vol.368
, pp. 1681-1688
-
-
Yoon, K.H.1
Lee, J.H.2
Kim, J.W.3
-
58
-
-
34249297625
-
The metabolic syndrome in South Asians: Continuing escalation & possible solutions
-
Misra A, Misra R, Wijesuriya M, et al. The metabolic syndrome in South Asians: Continuing escalation & possible solutions. Indian J Med Res 2007;125:345-354.
-
(2007)
Indian J Med Res
, vol.125
, pp. 345-354
-
-
Misra, A.1
Misra, R.2
Wijesuriya, M.3
-
59
-
-
44649143714
-
High prevalence of diabetes and cardiovascular risk factors associated with urbanization in India
-
Ramachandran A, Mary S, Yamuna A, et al. High prevalence of diabetes and cardiovascular risk factors associated with urbanization in India. Diabetes Care 2008;31: 893-898.
-
(2008)
Diabetes Care
, vol.31
, pp. 893-898
-
-
Ramachandran, A.1
Mary, S.2
Yamuna, A.3
-
60
-
-
0027448688
-
DNA polymorphisms of the apolipoprotein B gene are associated with obesity and serum lipids in healthy Indians in Singapore
-
Saha N, Tay JS, Heng CK, et al. DNA polymorphisms of the apolipoprotein B gene are associated with obesity and serum lipids in healthy Indians in Singapore. Clin Genet 1993;44:113-120.
-
(1993)
Clin Genet
, vol.44
, pp. 113-120
-
-
Saha, N.1
Tay, J.S.2
Heng, C.K.3
-
61
-
-
20444493880
-
Insights from the developing world: Thrifty genotypes and thrifty phenotypes
-
Prentice AM, Rayco-Solon P, Moore SE. Insights from the developing world: Thrifty genotypes and thrifty phenotypes. Proc Nutr Soc 2005;64:153-161.
-
(2005)
Proc Nutr Soc
, vol.64
, pp. 153-161
-
-
Prentice, A.M.1
Rayco-Solon, P.2
Moore, S.E.3
-
62
-
-
32144455202
-
The emerging epidemic of obesity in developing countries
-
Prentice AM. The emerging epidemic of obesity in developing countries. Int J Epidemiol 2006;35:93-99.
-
(2006)
Int J Epidemiol
, vol.35
, pp. 93-99
-
-
Prentice, A.M.1
-
63
-
-
34248652104
-
Search for genetic factors predisposing to atherogenic dyslipidemia
-
Yip AG, Ma Q, Wilcox M, et al. Search for genetic factors predisposing to atherogenic dyslipidemia. BMC Genet 2003;4(Suppl 1):S100.
-
(2003)
BMC Genet
, vol.4
, pp. S100
-
-
Yip, A.G.1
Ma, Q.2
Wilcox, M.3
-
64
-
-
78649664457
-
Prevalence and overlap of different lipid abnormalities in statin-treated patients at high cardiovascular risk in clinical practice in Germany
-
Gitt AK, Junger C, Smolka W, et al. Prevalence and overlap of different lipid abnormalities in statin-treated patients at high cardiovascular risk in clinical practice in Germany. Clin Res Cardiol 2010;99:723-733.
-
(2010)
Clin Res Cardiol
, vol.99
, pp. 723-733
-
-
Gitt, A.K.1
Junger, C.2
Smolka, W.3
-
65
-
-
27544487525
-
Prevalence and control of dyslipidemia among persons with diabetes in the United States
-
Jacobs MJ, Kleisli T, Pio JR, et al. Prevalence and control of dyslipidemia among persons with diabetes in the United States. Diabetes Res Clin Pract 2005;70:263-269.
-
(2005)
Diabetes Res Clin Pract
, vol.70
, pp. 263-269
-
-
Jacobs, M.J.1
Kleisli, T.2
Pio, J.R.3
-
66
-
-
0027406191
-
Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial
-
Stamler J, Vaccaro O, Neaton JD, et al. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993;16:434-444.
-
(1993)
Diabetes Care
, vol.16
, pp. 434-444
-
-
Stamler, J.1
Vaccaro, O.2
Neaton, J.D.3
-
67
-
-
11844278418
-
Is atherosclerosis in diabetes and impaired fasting glucose driven by elevated LDL cholesterol or by decreased HDL cholesterol?
-
Drexel H, Aczel S, Marte T, et al. Is atherosclerosis in diabetes and impaired fasting glucose driven by elevated LDL cholesterol or by decreased HDL cholesterol? Diabetes Care 2005;28:101-107.
-
(2005)
Diabetes Care
, vol.28
, pp. 101-107
-
-
Drexel, H.1
Aczel, S.2
Marte, T.3
-
68
-
-
80051769525
-
European panel on low density lipoprotein (LDL) subclasses: A statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses: Executive summary
-
Mikhailidis DP, Elisaf M, Rizzo M, et al. "European panel on low density lipoprotein (LDL) subclasses": A statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses: executive summary. Curr Vasc Pharmacol 2011;9:531-532.
-
(2011)
Curr Vasc Pharmacol
, vol.9
, pp. 531-532
-
-
Mikhailidis, D.P.1
Elisaf, M.2
Rizzo, M.3
-
69
-
-
19944397142
-
Is the diagnosis of metabolic syndrome useful for predicting cardiovascular disease in Asian diabetic patients? Analysis from the Japan Diabetes Complications Study
-
Sone H, Mizuno S, Fujii H, et al. Is the diagnosis of metabolic syndrome useful for predicting cardiovascular disease in Asian diabetic patients? Analysis from the Japan Diabetes Complications Study. Diabetes Care 2005;28:1463-1471.
-
(2005)
Diabetes Care
, vol.28
, pp. 1463-1471
-
-
Sone, H.1
Mizuno, S.2
Fujii, H.3
-
70
-
-
13744254491
-
Dyslipidemia in Asian Indians: Determinants and significance
-
Misra A, Luthra K, Vikram NK. Dyslipidemia in Asian Indians: Determinants and significance. J Assoc Physicians India 2004;52:137-142.
-
(2004)
J Assoc Physicians India
, vol.52
, pp. 137-142
-
-
Misra, A.1
Luthra, K.2
Vikram, N.K.3
-
72
-
-
79959272069
-
Cholesterol ester transfer protein and apolipoprotein e gene polymorphisms in hyperlipidemic Asian Indians in North India
-
Meena K, Misra A, Vikram N, et al. Cholesterol ester transfer protein and apolipoprotein E gene polymorphisms in hyperlipidemic Asian Indians in North India. Mol Cell Biochem 2011;352:189-196.
-
(2011)
Mol Cell Biochem
, vol.352
, pp. 189-196
-
-
Meena, K.1
Misra, A.2
Vikram, N.3
-
73
-
-
84865276881
-
Association of the myostatin gene with obesity, abdominal obesity and low lean body mass and in non-diabetic Asian Indians in North India
-
Bhatt SP, Nigam P, Misra A, et al. Association of the myostatin gene with obesity, abdominal obesity and low lean body mass and in non-diabetic Asian Indians in North India. PLoS One 2012;7:e40977.
-
(2012)
PLoS One
, vol.7
, pp. e40977
-
-
Bhatt, S.P.1
Nigam, P.2
Misra, A.3
-
74
-
-
58849121390
-
Apolipoprotein e gene polymorphism and dyslipidaemia in adult Asian Indians: A population based study from Calcutta, India
-
Das M, Pal S, Ghosh A. Apolipoprotein E gene polymorphism and dyslipidaemia in adult Asian Indians: A population based study from Calcutta, India. Indian J Hum Genet 2008;14:87-91.
-
(2008)
Indian J Hum Genet
, vol.14
, pp. 87-91
-
-
Das, M.1
Pal, S.2
Ghosh, A.3
-
75
-
-
84892729932
-
Assessment of 11-beta hydroxysteroid dehydrogenase (11-betaHSD1) 4478T→G and tumor necrosis factor-alpha (TNF-alpha)- 308G→A polymorphisms with obesity and insulin resistance in Asian Indians in North India
-
[Epub ahead of print]
-
Sharma M, Vikram NK, Misra A, et al. Assessment of 11-beta hydroxysteroid dehydrogenase (11-betaHSD1) 4478T→G and tumor necrosis factor-alpha (TNF-alpha)- 308G→A polymorphisms with obesity and insulin resistance in Asian Indians in North India. Mol Biol Rep 2013;[Epub ahead of print].
-
(2013)
Mol Biol Rep
-
-
Sharma, M.1
Vikram, N.K.2
Misra, A.3
-
76
-
-
32544443164
-
Review: Efficacy and mechanisms of action of statins in the treatment of diabetic dyslipidemia
-
Ginsberg HN. Review: Efficacy and mechanisms of action of statins in the treatment of diabetic dyslipidemia. J Clin Endocrinol Metab 2006;91:383-392.
-
(2006)
J Clin Endocrinol Metab
, vol.91
, pp. 383-392
-
-
Ginsberg, H.N.1
-
77
-
-
70350066787
-
The obesity, metabolic syndrome, and type 2 diabetes mellitus pandemic: II. Therapeutic management of atherogenic dyslipidemia
-
Ginsberg HN, MacCallum PR. The obesity, metabolic syndrome, and type 2 diabetes mellitus pandemic: II. Therapeutic management of atherogenic dyslipidemia. J Clin Hypertens (Greenwich) 2009;11:520-527.
-
(2009)
J Clin Hypertens (Greenwich)
, vol.11
, pp. 520-527
-
-
Ginsberg, H.N.1
MacCallum, P.R.2
-
78
-
-
48349134171
-
Effects of statins on high-density lipoproteins: A potential contribution to cardiovascular benefit
-
McTaggart F, Jones P. Effects of statins on high-density lipoproteins: A potential contribution to cardiovascular benefit. Cardiovasc Drugs Ther 2008;22:321-338.
-
(2008)
Cardiovasc Drugs Ther
, vol.22
, pp. 321-338
-
-
McTaggart, F.1
Jones, P.2
-
79
-
-
0035910051
-
Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S
-
Ballantyne CM, Olsson AG, Cook TJ, et al. Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S. Circulation 2001;104:3046-3051.
-
(2001)
Circulation
, vol.104
, pp. 3046-3051
-
-
Ballantyne, C.M.1
Olsson, A.G.2
Cook, T.J.3
-
80
-
-
0034604225
-
Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: The Bezafibrate Infarction Prevention (BIP) study
-
BIP Study Group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: The Bezafibrate Infarction Prevention (BIP) study. Circulation 2000;102:21-27.
-
(2000)
Circulation
, vol.102
, pp. 21-27
-
-
-
81
-
-
33646829645
-
Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: Meta-analysis of randomised controlled trials
-
Costa J, Borges M, David C, et al. Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: Meta-analysis of randomised controlled trials. BMJ 2006;332:1115-1124.
-
(2006)
BMJ
, vol.332
, pp. 1115-1124
-
-
Costa, J.1
Borges, M.2
David, C.3
-
82
-
-
33748303084
-
Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: Analysis of the Treating to New Targets study
-
Deedwania P, Barter P, Carmena R, et al. Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: Analysis of the Treating to New Targets study. Lancet 2006;368:919-928.
-
(2006)
Lancet
, vol.368
, pp. 919-928
-
-
Deedwania, P.1
Barter, P.2
Carmena, R.3
-
83
-
-
0032572086
-
Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study
-
Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998;279:1615-1622.
-
(1998)
JAMA
, vol.279
, pp. 1615-1622
-
-
Downs, J.R.1
Clearfield, M.2
Weis, S.3
-
84
-
-
0023232216
-
Helsinki heart study: Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease
-
Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987;317:1237-1245.
-
(1987)
N Engl J Med
, vol.317
, pp. 1237-1245
-
-
Frick, M.H.1
Elo, O.2
Haapa, K.3
-
85
-
-
26444447495
-
Impact of statins in microalbuminuric subjects with the metabolic syndrome: A substudy of the PREVEND Intervention Trial
-
Geluk CA, Asselbergs FW, Hillege HL, et al. Impact of statins in microalbuminuric subjects with the metabolic syndrome: A substudy of the PREVEND Intervention Trial. Eur Heart J 2005;26:1314-1320.
-
(2005)
Eur Heart J
, vol.26
, pp. 1314-1320
-
-
Geluk, C.A.1
Asselbergs, F.W.2
Hillege, H.L.3
-
86
-
-
77951704587
-
Effects of combination lipid therapy in type 2 diabetes mellitus
-
Ginsberg HN, Elam MB, Lovato LC, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010;362:1563-1574.
-
(2010)
N Engl J Med
, vol.362
, pp. 1563-1574
-
-
Ginsberg, H.N.1
Elam, M.B.2
Lovato, L.C.3
-
87
-
-
28044452217
-
Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): Randomised controlled trial
-
Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): Randomised controlled trial. Lancet 2005;366:1849-1861
-
(2005)
Lancet
, vol.366
, pp. 1849-1861
-
-
Keech, A.1
Simes, R.J.2
Barter, P.3
-
88
-
-
33750159238
-
-
Erratum in: Lancet 2006;368:1415
-
(2006)
Lancet
, vol.368
, pp. 1415
-
-
-
89
-
-
79960700766
-
Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: A meta-analysis
-
Lee M, Saver JL, Towfighi A, et al. Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: A meta-analysis. Atherosclerosis 2011;217: 492-498.
-
(2011)
Atherosclerosis
, vol.217
, pp. 492-498
-
-
Lee, M.1
Saver, J.L.2
Towfighi, A.3
-
90
-
-
0026597808
-
Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment
-
Manninen V, Tenkanen L, Koskinen P, et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation 1992;85:37-45.
-
(1992)
Circulation
, vol.85
, pp. 37-45
-
-
Manninen, V.1
Tenkanen, L.2
Koskinen, P.3
-
91
-
-
0033527030
-
Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group
-
Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999;341: 410-418.
-
(1999)
N Engl J Med
, vol.341
, pp. 410-418
-
-
Rubins, H.B.1
Robins, S.J.2
Collins, D.3
-
92
-
-
0037420492
-
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOTLLA): A multicentre randomised controlled trial
-
Sever PS, Dahlöf B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOTLLA): A multicentre randomised controlled trial. Lancet 2003;361:1149-1158.
-
(2003)
Lancet
, vol.361
, pp. 1149-1158
-
-
Sever, P.S.1
Dahlöf, B.2
Poulter, N.R.3
-
93
-
-
0028883828
-
Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group
-
Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301-1307.
-
(1995)
N Engl J Med
, vol.333
, pp. 1301-1307
-
-
Shepherd, J.1
Cobbe, S.M.2
Ford, I.3
-
94
-
-
0037840242
-
MRC/BHF heart protection study of cholesterol-lowering with simvastatin in 5963 people with diabetes: A randomised placebocontrolled trial
-
Collins R, Armitage J, Parish S, et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: A randomised placebocontrolled trial. Lancet 2003;361:2005-2016.
-
(2003)
Lancet
, vol.361
, pp. 2005-2016
-
-
Collins, R.1
Armitage, J.2
Parish, S.3
-
95
-
-
78751640788
-
Meta-analysis: Statin therapy does not alter the association between low levels of high-density lipoprotein cholesterol and increased cardiovascular risk
-
Jafri H, Alsheikh-Ali AA, Karas RH. Meta-analysis: Statin therapy does not alter the association between low levels of high-density lipoprotein cholesterol and increased cardiovascular risk. Ann Intern Med 2010;153: 800-808.
-
(2010)
Ann Intern Med
, vol.153
, pp. 800-808
-
-
Jafri, H.1
Alsheikh-Ali, A.A.2
Karas, R.H.3
-
96
-
-
84877730804
-
How to control residual cardiovascular risk despite statin treatment: Focusing on HDL-cholesterol
-
Lim S, Park YM, Sakuma I, et al. How to control residual cardiovascular risk despite statin treatment: Focusing on HDL-cholesterol. Int J Cardiol 2013;166:8-14.
-
(2013)
Int J Cardiol
, vol.166
, pp. 8-14
-
-
Lim, S.1
Park, Y.M.2
Sakuma, I.3
-
97
-
-
84899970979
-
Atherogenic dyslipidemia and residual cardiovascular risk in statintreated patients
-
Sirimarco G, Labreuche J, Bruckert E, et al. Atherogenic dyslipidemia and residual cardiovascular risk in statintreated patients. Stroke 2014;45:1429-1436.
-
(2014)
Stroke
, vol.45
, pp. 1429-1436
-
-
Sirimarco, G.1
Labreuche, J.2
Bruckert, E.3
-
98
-
-
33846464226
-
Safety and efficacy of statins in Asians
-
Liao JK. Safety and efficacy of statins in Asians. Am J Cardiol 2007;99:410-414.
-
(2007)
Am J Cardiol
, vol.99
, pp. 410-414
-
-
Liao, J.K.1
-
99
-
-
33748952489
-
Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): A prospective randomised controlled trial
-
Nakamura H, Arakawa K, Itakura H, et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): A prospective randomised controlled trial. Lancet 2006;368:1155-1163.
-
(2006)
Lancet
, vol.368
, pp. 1155-1163
-
-
Nakamura, H.1
Arakawa, K.2
Itakura, H.3
-
100
-
-
80053338005
-
Ethnic variations in lipid-lowering in response to a statin (EVIREST): A substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)
-
Chapman N, Chang CL, Caulfield M, et al. Ethnic variations in lipid-lowering in response to a statin (EVIREST): A substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). Ethn Dis 2011;21:150-157.
-
(2011)
Ethn Dis
, vol.21
, pp. 150-157
-
-
Chapman, N.1
Chang, C.L.2
Caulfield, M.3
-
101
-
-
78449281377
-
Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170,000 participants in 26 randomised trials
-
Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010;376:1670-1681.
-
(2010)
Lancet
, vol.376
, pp. 1670-1681
-
-
Baigent, C.1
Blackwell, L.2
Emberson, J.3
-
102
-
-
84930670749
-
Lack of effect of lowering LDL cholesterol on cancer: Metaanalysis of individual data from 175,000 people in 27 randomised trials of statin therapy
-
Emberson JR, Kearney PM, Blackwell L, et al. Lack of effect of lowering LDL cholesterol on cancer: Metaanalysis of individual data from 175,000 people in 27 randomised trials of statin therapy. PLoS One 2012;7: e29849.
-
(2012)
PLoS One
, vol.7
, pp. e29849
-
-
Emberson, J.R.1
Kearney, P.M.2
Blackwell, L.3
-
103
-
-
85027957106
-
Lipid-lowering therapies, glucose control and incident diabetes: Evidence, mechanisms and clinical implications
-
Zafrir B, Jain M. Lipid-lowering therapies, glucose control and incident diabetes: Evidence, mechanisms and clinical implications. Cardiovasc Drugs Ther 2014;28: 361-377.
-
(2014)
Cardiovasc Drugs Ther
, vol.28
, pp. 361-377
-
-
Zafrir, B.1
Jain, M.2
-
104
-
-
77549087054
-
Statins and risk of incident diabetes: A collaborative meta-analysis of randomised statin trials
-
Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: A collaborative meta-analysis of randomised statin trials. Lancet 2010;375:735-742.
-
(2010)
Lancet
, vol.375
, pp. 735-742
-
-
Sattar, N.1
Preiss, D.2
Murray, H.M.3
-
105
-
-
84892187236
-
Diabetogenic effect of statins: A double-edged sword?
-
Yoon JS, Lee HW. Diabetogenic effect of statins: a double-edged sword? Diabetes Metab J 2013;37:415-422.
-
(2013)
Diabetes Metab J
, vol.37
, pp. 415-422
-
-
Yoon, J.S.1
Lee, H.W.2
-
106
-
-
27444443876
-
Diagnosis and management of the metabolic syndrome: An American heart association/national heart, lung, and blood institute scientific statement
-
Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005;112:2735-2752.
-
(2005)
Circulation
, vol.112
, pp. 2735-2752
-
-
Grundy, S.M.1
Cleeman, J.I.2
Daniels, S.R.3
-
107
-
-
84892649479
-
Standards of medical care in diabetes-2014
-
American Diabetes Association. Standards of medical care in diabetes-2014. Diabetes Care 2014;37(Suppl 1): S14-S80.
-
(2014)
Diabetes Care
, vol.37
, pp. S14-S80
-
-
-
108
-
-
56249123656
-
The residual risk reduction initiative: A call to action to reduce residual vascular risk in dyslipidaemic patient
-
Fruchart JC, Sacks FM, Hermans MP, et al. The Residual Risk Reduction Initiative: A call to action to reduce residual vascular risk in dyslipidaemic patient. Diab Vasc Dis Res 2008;5:319-335.
-
(2008)
Diab Vasc Dis Res
, vol.5
, pp. 319-335
-
-
Fruchart, J.C.1
Sacks, F.M.2
Hermans, M.P.3
-
109
-
-
33749536035
-
Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: Therapeutic options beyond statins
-
Tenenbaum A, Fisman EZ, Motro M, et al. Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: Therapeutic options beyond statins. Cardiovasc Diabetol 2006;5:20.
-
(2006)
Cardiovasc Diabetol
, vol.5
, pp. 20
-
-
Tenenbaum, A.1
Fisman, E.Z.2
Motro, M.3
-
110
-
-
77952708442
-
Effects of fibrates on cardiovascular outcomes: A systematic review and metaanalysis
-
Jun M, Foote C, Lv J, et al. Effects of fibrates on cardiovascular outcomes: A systematic review and metaanalysis. Lancet 2010;375:1875-1884.
-
(2010)
Lancet
, vol.375
, pp. 1875-1884
-
-
Jun, M.1
Foote, C.2
Lv, J.3
-
111
-
-
0032506273
-
Mechanism of action of fibrates on lipid and lipoprotein metabolism
-
Staels B, Dallongeville J, Auwerx J, et al. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 1998;98:2088-2093.
-
(1998)
Circulation
, vol.98
, pp. 2088-2093
-
-
Staels, B.1
Dallongeville, J.2
Auwerx, J.3
-
112
-
-
0342506477
-
Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) Study Group
-
Frick MH, Syvanne M, Nieminen MS, et al. Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) Study Group. Circulation 1997;96:2137-2143.
-
(1997)
Circulation
, vol.96
, pp. 2137-2143
-
-
Frick, M.H.1
Syvanne, M.2
Nieminen, M.S.3
-
113
-
-
84867235189
-
Fibrates are an essential part of modern anti-dyslipidemic arsenal: Spotlight on atherogenic dyslipidemia and residual risk reduction
-
Tenenbaum A, Fisman EZ. Fibrates are an essential part of modern anti-dyslipidemic arsenal: Spotlight on atherogenic dyslipidemia and residual risk reduction. Cardiovasc Diabetol 2012;11:125.
-
(2012)
Cardiovasc Diabetol
, vol.11
, pp. 125
-
-
Tenenbaum, A.1
Fisman, E.Z.2
-
114
-
-
64749095070
-
Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study
-
Scott R, O'Brien R, Fulcher G, et al. Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetes Care 2009;32:493-498.
-
(2009)
Diabetes Care
, vol.32
, pp. 493-498
-
-
Scott, R.1
O'Brien, R.2
Fulcher, G.3
-
115
-
-
19344375593
-
Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome
-
Tenenbaum A, Motro M, Fisman EZ, et al. Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome. Arch Intern Med 2005; 165:1154-1160.
-
(2005)
Arch Intern Med
, vol.165
, pp. 1154-1160
-
-
Tenenbaum, A.1
Motro, M.2
Fisman, E.Z.3
-
116
-
-
82855161011
-
Dyslipidaemia of obesity, metabolic syndrome and type 2 diabetes mellitus: The case for residual risk reduction after statin treatment
-
Athyros VG, Tziomalos K, Karagiannis A, et al. Dyslipidaemia of obesity, metabolic syndrome and type 2 diabetes mellitus: The case for residual risk reduction after statin treatment. Open Cardiovasc Med J 2011;5:24-34.
-
(2011)
Open Cardiovasc Med J
, vol.5
, pp. 24-34
-
-
Athyros, V.G.1
Tziomalos, K.2
Karagiannis, A.3
-
117
-
-
27744605739
-
Pharmacokinetic interactions between statins and fibrates
-
Corsini A, Bellosta S, Davidson MH. Pharmacokinetic interactions between statins and fibrates. Am J Cardiol 2005;96:44K-49K.
-
(2005)
Am J Cardiol
, vol.96
, pp. 44K-49K
-
-
Corsini, A.1
Bellosta, S.2
Davidson, M.H.3
-
118
-
-
84873249294
-
Case report of exercise and statin-fibrate combination therapy-caused myopathy in a patient with metabolic syndrome: Contradictions between the two main therapeutic pathways
-
Laszlo A, Kalabay L, Nemcsik J. Case report of exercise and statin-fibrate combination therapy-caused myopathy in a patient with metabolic syndrome: Contradictions between the two main therapeutic pathways. BMC Res Notes 2013;6:52.
-
(2013)
BMC Res Notes
, vol.6
, pp. 52
-
-
Laszlo, A.1
Kalabay, L.2
Nemcsik, J.3
-
120
-
-
0037626887
-
Niacin and cholesterol: Role in cardiovascular disease (review)
-
Ganji SH, Kamanna VS, Kashyap ML. Niacin and cholesterol: Role in cardiovascular disease (review). J Nutr Biochem 2003;14:298-305.
-
(2003)
J Nutr Biochem
, vol.14
, pp. 298-305
-
-
Ganji, S.H.1
Kamanna, V.S.2
Kashyap, M.L.3
-
121
-
-
70350516769
-
Effects of high-dose modified-release nicotinic acid on atherosclerosis and vascular function: A randomized, placebo-controlled, magnetic resonance imaging study
-
Lee JM, Robson MD, Yu LM, et al. Effects of high-dose modified-release nicotinic acid on atherosclerosis and vascular function: A randomized, placebo-controlled, magnetic resonance imaging study. J Am Coll Cardiol 2009;54:1787-1794.
-
(2009)
J Am Coll Cardiol
, vol.54
, pp. 1787-1794
-
-
Lee, J.M.1
Robson, M.D.2
Yu, L.M.3
-
122
-
-
77953121328
-
The ARBITER 6-HALTS trial (Arterial biology for the investigation of the treatment effects of reducing cholesterol 6-HDL and LDL treatment strategies in atherosclerosis): Final results and the impact of medication adherence, dose, and treatment duration
-
Villines TC, Stanek EJ, Devine PJ, et al. The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): Final results and the impact of medication adherence, dose, and treatment duration. J Am Coll Cardiol 2010;55:2721-2726.
-
(2010)
J Am Coll Cardiol
, vol.55
, pp. 2721-2726
-
-
Villines, T.C.1
Stanek, E.J.2
Devine, P.J.3
-
123
-
-
0016630250
-
Clofibrate and niacin in coronary heart disease
-
Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA 1975;231:360-381.
-
(1975)
JAMA
, vol.231
, pp. 360-381
-
-
-
124
-
-
84855171302
-
Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy
-
Boden WE, Probstfield JL, Anderson T, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011;365:2255-2267.
-
(2011)
N Engl J Med
, vol.365
, pp. 2255-2267
-
-
Boden, W.E.1
Probstfield, J.L.2
Anderson, T.3
-
125
-
-
0035969564
-
Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease
-
Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001;345: 1583-1592.
-
(2001)
N Engl J Med
, vol.345
, pp. 1583-1592
-
-
Brown, B.G.1
Zhao, X.Q.2
Chait, A.3
-
126
-
-
0025183769
-
Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B
-
Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990;323:1289-1298.
-
(1990)
N Engl J Med
, vol.323
, pp. 1289-1298
-
-
Brown, G.1
Albers, J.J.2
Fisher, L.D.3
-
127
-
-
77952397461
-
Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis
-
Bruckert E, Labreuche J, Amarenco P. Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis. Atherosclerosis 2010;210:353-361.
-
(2010)
Atherosclerosis
, vol.210
, pp. 353-361
-
-
Bruckert, E.1
Labreuche, J.2
Amarenco, P.3
-
128
-
-
0023001772
-
Fifteen year mortality in coronary drug project patients: Long-term benefit with niacin
-
Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in Coronary Drug Project patients: Long-term benefit with niacin. J Am Coll Cardiol 1986;8:1245-1255.
-
(1986)
J Am Coll Cardiol
, vol.8
, pp. 1245-1255
-
-
Canner, P.L.1
Berge, K.G.2
Wenger, N.K.3
-
129
-
-
0034644442
-
Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: The ADMIT study: A randomized trial. Arterial Disease Multiple Intervention Trial
-
Elam MB, Hunninghake DB, Davis KB, et al. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: The ADMIT study: A randomized trial. Arterial Disease Multiple Intervention Trial. JAMA 2000;284:1263-1270.
-
(2000)
JAMA
, vol.284
, pp. 1263-1270
-
-
Elam, M.B.1
Hunninghake, D.B.2
Davis, K.B.3
-
130
-
-
0037158150
-
Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: Results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial
-
Grundy SM, Vega GL, McGovern ME, et al. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: Results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. Arch Intern Med 2002;162:1568-1576.
-
(2002)
Arch Intern Med
, vol.162
, pp. 1568-1576
-
-
Grundy, S.M.1
Vega, G.L.2
McGovern, M.E.3
-
131
-
-
84904252744
-
Effects of extended-release niacin with laropiprant in high-risk patients
-
HPS2-THRIVE Collaborative Group, Haynes R, Hopewell JC, et al. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med 2014;371: 203-212.
-
(2014)
N Engl J Med
, vol.371
, pp. 203-212
-
-
Haynes, R.1
Hopewell, J.C.2
-
132
-
-
42149136762
-
Effects of niacin on glucose control in patients with dyslipidemia
-
Goldberg RB, Jacobson TA. Effects of niacin on glucose control in patients with dyslipidemia. Mayo Clin Proc 2008;83:470-478.
-
(2008)
Mayo Clin Proc
, vol.83
, pp. 470-478
-
-
Goldberg, R.B.1
Jacobson, T.A.2
-
133
-
-
84862107330
-
Effect of extended-release niacin on new-onset diabetes among hyperlipidemic patients treated with ezetimibe/simvastatin in a randomized controlled trial
-
Guyton JR, Fazio S, Adewale AJ, et al. Effect of extended-release niacin on new-onset diabetes among hyperlipidemic patients treated with ezetimibe/simvastatin in a randomized controlled trial. Diabetes Care 2012;35: 857-860.
-
(2012)
Diabetes Care
, vol.35
, pp. 857-860
-
-
Guyton, J.R.1
Fazio, S.2
Adewale, A.J.3
-
134
-
-
84875540714
-
Effects of niacin on the incidence of new onset diabetes and cardiovascular events in patients with normoglycaemia and impaired fasting glucose
-
Sazonov V, Maccubbin D, Sisk CM, et al. Effects of niacin on the incidence of new onset diabetes and cardiovascular events in patients with normoglycaemia and impaired fasting glucose. Int J Clin Pract 2013;67:297-302.
-
(2013)
Int J Clin Pract
, vol.67
, pp. 297-302
-
-
Sazonov, V.1
MacCubbin, D.2
Sisk, C.M.3
-
136
-
-
84904265666
-
Safety profile of extended-release niacin in the AIMHIGH trial
-
Anderson TJ, Boden WE, Desvigne-Nickens P, et al. Safety profile of extended-release niacin in the AIMHIGH trial. N Engl J Med 2014;371:288-290.
-
(2014)
N Engl J Med
, vol.371
, pp. 288-290
-
-
Anderson, T.J.1
Boden, W.E.2
Desvigne-Nickens, P.3
-
137
-
-
0037137299
-
Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease
-
Kris-Etherton PM, Harris WS, Appel LJ. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation 2002;106:2747-2757.
-
(2002)
Circulation
, vol.106
, pp. 2747-2757
-
-
Kris-Etherton, P.M.1
Harris, W.S.2
Appel, L.J.3
-
138
-
-
0024363690
-
Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: Diet and reinfarction trial (DART)
-
Burr ML, Fehily AM, Gilbert JF, et al. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: Diet and reinfarction trial (DART). Lancet 1989;2:757-761.
-
(1989)
Lancet
, vol.2
, pp. 757-761
-
-
Burr, M.L.1
Fehily, A.M.2
Gilbert, J.F.3
-
139
-
-
0345109256
-
Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin e after myocardial infarction: Results of the GISSIPrevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico
-
GISSI-Prevenzione Investigators. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: Results of the GISSIPrevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet 1999;354: 447-455.
-
(1999)
Lancet
, vol.354
, pp. 447-455
-
-
-
140
-
-
33947583493
-
Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): A randomised open-label, blinded endpoint analysis
-
Yokoyama M, Origasa H, Matsuzaki M, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): A randomised open-label, blinded endpoint analysis. Lancet 2007;369: 1090-1098.
-
(2007)
Lancet
, vol.369
, pp. 1090-1098
-
-
Yokoyama, M.1
Origasa, H.2
Matsuzaki, M.3
-
141
-
-
84866124338
-
Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study)
-
Ballantyne CM, Bays HE, Kastelein JJ, et al. Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study). Am J Cardiol 2012; 110:984-992.
-
(2012)
Am J Cardiol
, vol.110
, pp. 984-992
-
-
Ballantyne, C.M.1
Bays, H.E.2
Kastelein, J.J.3
-
142
-
-
80051784104
-
Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial)
-
Bays HE, Ballantyne CM, Kastelein JJ, et al. Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial). Am J Cardiol 2011;108:682-690.
-
(2011)
Am J Cardiol
, vol.108
, pp. 682-690
-
-
Bays, H.E.1
Ballantyne, C.M.2
Kastelein, J.J.3
-
143
-
-
78549233384
-
N-3 Fatty acids and cardiovascular events after myocardial infarction
-
Kromhout D, Giltay EJ, Geleijnse JM, et al. n-3 Fatty acids and cardiovascular events after myocardial infarction. N Engl J Med 2010;363:2015-2026.
-
(2010)
N Engl J Med
, vol.363
, pp. 2015-2026
-
-
Kromhout, D.1
Giltay, E.J.2
Geleijnse, J.M.3
-
144
-
-
84864219466
-
N-3 fatty acids and cardiovascular outcomes in patients with dysglycemia
-
Bosch J, Gerstein HC, Dagenais GR, et al. n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med 2012;367:309-318.
-
(2012)
N Engl J Med
, vol.367
, pp. 309-318
-
-
Bosch, J.1
Gerstein, H.C.2
Dagenais, G.R.3
-
145
-
-
84877624255
-
N-3 fatty acids in patients with multiple cardiovascular risk factors
-
Roncaglioni MC, Tombesi M, Avanzini F, et al. n-3 fatty acids in patients with multiple cardiovascular risk factors. N Engl J Med 2013;368:1800-1808.
-
(2013)
N Engl J Med
, vol.368
, pp. 1800-1808
-
-
Roncaglioni, M.C.1
Tombesi, M.2
Avanzini, F.3
-
146
-
-
33645566760
-
Risks and benefits of omega 3 fats for mortality, cardiovascular disease, and cancer: Systematic review
-
Hooper L, Thompson RL, Harrison RA, et al. Risks and benefits of omega 3 fats for mortality, cardiovascular disease, and cancer: Systematic review. BMJ 2006;332: 752-760.
-
(2006)
BMJ
, vol.332
, pp. 752-760
-
-
Hooper, L.1
Thompson, R.L.2
Harrison, R.A.3
-
147
-
-
78650169331
-
OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction
-
Rauch B, Schiele R, Schneider S, et al. OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction. Circulation 2010;122:2152-2159.
-
(2010)
Circulation
, vol.122
, pp. 2152-2159
-
-
Rauch, B.1
Schiele, R.2
Schneider, S.3
-
148
-
-
84871014821
-
Patient with hypertriglyceridemia, type 2 diabetes, and chronic kidney disease treated with atorvastatin and omega-3 fatty acid ethyl esters
-
Athyros VG, Mikhailidis DP. Patient with hypertriglyceridemia, type 2 diabetes, and chronic kidney disease treated with atorvastatin and omega-3 fatty acid ethyl esters. Open Cardiovasc Med J 2012;6:122-125.
-
(2012)
Open Cardiovasc Med J
, vol.6
, pp. 122-125
-
-
Athyros, V.G.1
Mikhailidis, D.P.2
-
149
-
-
34548319692
-
Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: An 8-week, randomized, double-blind, placebocontrolled study
-
Davidson MH, Stein EA, Bays HE, et al. Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: An 8-week, randomized, double-blind, placebocontrolled study. Clin Ther 2007;29:1354-1367.
-
(2007)
Clin Ther
, vol.29
, pp. 1354-1367
-
-
Davidson, M.H.1
Stein, E.A.2
Bays, H.E.3
-
150
-
-
84884355278
-
A highly bioavailable omega-3 free fatty acid formulation improves the cardiovascular risk profile in high-risk, statin-treated patients with residual hypertriglyceridemia (the ESPRIT trial)
-
Maki KC, Orloff DG, Nicholls SJ, et al. A highly bioavailable omega-3 free fatty acid formulation improves the cardiovascular risk profile in high-risk, statin-treated patients with residual hypertriglyceridemia (the ESPRIT trial). Clin Ther 2013;35:1400-1411.
-
(2013)
Clin Ther
, vol.35
, pp. 1400-1411
-
-
Maki, K.C.1
Orloff, D.G.2
Nicholls, S.J.3
-
151
-
-
0030862755
-
Randomized, double-blind, placebo-controlled trial of fish oil and mustard oil in patients with suspected acute myocardial infarction: The Indian experiment of infarct survival-4
-
Singh RB, Niaz MA, Sharma JP, et al. Randomized, double-blind, placebo-controlled trial of fish oil and mustard oil in patients with suspected acute myocardial infarction: The Indian experiment of infarct survival-4. Cardiovasc Drugs Ther 1997;11:485-491.
-
(1997)
Cardiovasc Drugs Ther
, vol.11
, pp. 485-491
-
-
Singh, R.B.1
Niaz, M.A.2
Sharma, J.P.3
-
152
-
-
49749128376
-
Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: Sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS)
-
Saito Y, Yokoyama M, Origasa H, et al. Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: Sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS). Atherosclerosis 2008;200:135-140.
-
(2008)
Atherosclerosis
, vol.200
, pp. 135-140
-
-
Saito, Y.1
Yokoyama, M.2
Origasa, H.3
-
153
-
-
84872416659
-
Omega-3 fatty acids and mortality outcome in patients with and without type 2 diabetes after myocardial infarction:Aretrospective, matched-cohort study
-
Poole CD, Halcox JP, Jenkins-Jones S, et al. Omega-3 fatty acids and mortality outcome in patients with and without type 2 diabetes after myocardial infarction:Aretrospective, matched-cohort study. Clin Ther 2013;35:40-51.
-
(2013)
Clin Ther
, vol.35
, pp. 40-51
-
-
Poole, C.D.1
Halcox, J.P.2
Jenkins-Jones, S.3
-
154
-
-
33645007540
-
Intake of fish and n3 fatty acids and risk of coronary heart disease among Japanese: The Japan Public Health Center-Based (JPHC) Study Cohort I
-
Iso H, Kobayashi M, Ishihara J, et al. Intake of fish and n3 fatty acids and risk of coronary heart disease among Japanese: The Japan Public Health Center-Based (JPHC) Study Cohort I. Circulation 2006;113:195-202.
-
(2006)
Circulation
, vol.113
, pp. 195-202
-
-
Iso, H.1
Kobayashi, M.2
Ishihara, J.3
-
155
-
-
36348975228
-
Effects of torcetrapib in patients at high risk for coronary events
-
Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007;357:2109-2122.
-
(2007)
N Engl J Med
, vol.357
, pp. 2109-2122
-
-
Barter, P.J.1
Caulfield, M.2
Eriksson, M.3
-
156
-
-
84870045994
-
Effects of dalcetrapib in patients with a recent acute coronary syndrome
-
Schwartz GG, Olsson AG, Abt M, et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 2012;367:2089-2099.
-
(2012)
N Engl J Med
, vol.367
, pp. 2089-2099
-
-
Schwartz, G.G.1
Olsson, A.G.2
Abt, M.3
-
157
-
-
84920525718
-
Elevated cholesteryl ester transfer protein (CETP) activity, a major determinant of the atherogenic dyslipidemia, and atherosclerotic cardiovascular disease in South Asians
-
2047487314528461. First Published March 21, 2014
-
Rashid S, Sniderman A, Melone M, et al. Elevated cholesteryl ester transfer protein (CETP) activity, a major determinant of the atherogenic dyslipidemia, and atherosclerotic cardiovascular disease in South Asians. Eur J Prev Cardiol 2014;2047487314528461. First Published March 21, 2014.
-
(2014)
Eur J Prev Cardiol
-
-
Rashid, S.1
Sniderman, A.2
Melone, M.3
-
158
-
-
79959746706
-
The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): A randomised placebo-controlled trial
-
Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011;377:2181-2192.
-
(2011)
Lancet
, vol.377
, pp. 2181-2192
-
-
Baigent, C.1
Landray, M.J.2
Reith, C.3
-
159
-
-
50949102416
-
Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): Comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes
-
Cannon CP, Giugliano RP, Blazing MA, et al. Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): Comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. Am Heart J 2008;156:826-832.
-
(2008)
Am Heart J
, vol.156
, pp. 826-832
-
-
Cannon, C.P.1
Giugliano, R.P.2
Blazing, M.A.3
-
160
-
-
41649107358
-
Simvastatin with or without ezetimibe in familial hypercholesterolemia
-
Kastelein JJ, Akdim F, Stroes ES, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008;358:1431-1443.
-
(2008)
N Engl J Med
, vol.358
, pp. 1431-1443
-
-
Kastelein, J.J.1
Akdim, F.2
Stroes, E.S.3
-
161
-
-
44349126634
-
The cholesterol absorption inhibitor ezetimibe acts by blocking the sterol-induced internalization of NPC1L1
-
Ge L, Wang J, Qi W, et al. The cholesterol absorption inhibitor ezetimibe acts by blocking the sterol-induced internalization of NPC1L1. Cell Metab 2008;7:508-519.
-
(2008)
Cell Metab
, vol.7
, pp. 508-519
-
-
Ge, L.1
Wang, J.2
Qi, W.3
-
162
-
-
84905040766
-
Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: Final baseline characteristics of the IMPROVE-IT study population
-
Blazing MA, Giugliano RP, Cannon CP, et al. Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: Final baseline characteristics of the IMPROVE-IT study population. Am Heart J 2014;168: 205-212.
-
(2014)
Am Heart J
, vol.168
, pp. 205-212
-
-
Blazing, M.A.1
Giugliano, R.P.2
Cannon, C.P.3
-
163
-
-
84858638369
-
Effect of a monoclonal antibody to PCSK9 on LDL cholesterol
-
Stein EA, Mellis S, Yancopoulos GD, et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med 2012;366:1108-1118.
-
(2012)
N Engl J Med
, vol.366
, pp. 1108-1118
-
-
Stein, E.A.1
Mellis, S.2
Yancopoulos, G.D.3
-
164
-
-
84863494422
-
Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: A phase 2 randomised controlled trial
-
Stein EA, Gipe D, Bergeron J, et al. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: A phase 2 randomised controlled trial. Lancet 2012;380:29-36.
-
(2012)
Lancet
, vol.380
, pp. 29-36
-
-
Stein, E.A.1
Gipe, D.2
Bergeron, J.3
-
165
-
-
84871326497
-
Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: The GAUSS randomized trial
-
Sullivan D, Olsson AG, Scott R, et al. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: The GAUSS randomized trial. JAMA 2012;308:1-10.
-
(2012)
JAMA
, vol.308
, pp. 1-10
-
-
Sullivan, D.1
Olsson, A.G.2
Scott, R.3
-
166
-
-
84869220345
-
Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/Kexin Type 9 serine protease in patients with heterozygous familial hypercholesterolemia: The reduction of LDL-C with PCSK9 inhibition in heterozygous familial hypercholesterolemia disorder (RUTHERFORD) randomized trial
-
Raal F, Scott R, Somaratne R, et al. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/Kexin Type 9 serine protease in patients with heterozygous familial hypercholesterolemia: The reduction of LDL-C with PCSK9 inhibition in heterozygous familial hypercholesterolemia disorder (RUTHERFORD) randomized trial. Circulation 2012;126:2408-2417.
-
(2012)
Circulation
, vol.126
, pp. 2408-2417
-
-
Raal, F.1
Scott, R.2
Somaratne, R.3
-
167
-
-
84871995815
-
Standards of medical care in diabetes-2013
-
American Diabetes Association. Standards of medical care in diabetes-2013. Diabetes Care 2013;36 Suppl 1: S11-S66.
-
(2013)
Diabetes Care
, vol.36
, pp. S11-S66
-
-
-
168
-
-
84860144206
-
American association of clinical endocrinologists' guidelines for management of dyslipidemia and prevention of atherosclerosis
-
Jellinger PS, Smith DA, Mehta AE, et al. American Association of Clinical Endocrinologists' Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis. Endocr Pract 2012;18(Suppl 1):1-78.
-
(2012)
Endocr Pract
, vol.18
, pp. 1-78
-
-
Jellinger, P.S.1
Smith, D.A.2
Mehta, A.E.3
-
169
-
-
84880422112
-
Frequency of nut consumption and mortality risk in the PREDIMED nutrition intervention trial
-
Guasch-Ferre M, Bullo M, Martinez-Gonzalez MA, et al. Frequency of nut consumption and mortality risk in the PREDIMED nutrition intervention trial. BMC Med 2013; 11:164.
-
(2013)
BMC Med
, vol.11
, pp. 164
-
-
Guasch-Ferre, M.1
Bullo, M.2
Martinez-Gonzalez, M.A.3
-
170
-
-
84902576469
-
2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines
-
Stone NJ, Robinson J, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013;63:2889-2934.
-
(2013)
J Am Coll Cardiol
, vol.63
, pp. 2889-2934
-
-
Stone, N.J.1
Robinson, J.2
Lichtenstein, A.H.3
-
171
-
-
84921441124
-
-
American Association of Clinical Endocrinologists. Member alert regarding new guidelines. 2013. Available at https://www.aace.com/sites/all/files/Member-Alert-Re-Guidelines-112113.pdf
-
(2013)
Member Alert Regarding New Guidelines
-
-
-
172
-
-
84898950294
-
The ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: The good the bad and the uncertain: A comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011
-
Ray KK, Kastelein JJ, Boekholdt SM, et al. The ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: The good the bad and the uncertain: A comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011. Eur Heart J 2014;35:960-968.
-
(2014)
Eur Heart J
, vol.35
, pp. 960-968
-
-
Ray, K.K.1
Kastelein, J.J.2
Boekholdt, S.M.3
|